US Bancorp DE Has $1.46 Million Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

US Bancorp DE grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 11.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,588 shares of the company’s stock after purchasing an additional 10,925 shares during the quarter. US Bancorp DE’s holdings in Takeda Pharmaceutical were worth $1,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in TAK. Ballentine Partners LLC boosted its holdings in shares of Takeda Pharmaceutical by 48.9% during the 3rd quarter. Ballentine Partners LLC now owns 31,094 shares of the company’s stock worth $442,000 after buying an additional 10,205 shares in the last quarter. McAdam LLC acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter valued at $183,000. Signaturefd LLC boosted its stake in Takeda Pharmaceutical by 28.6% during the third quarter. Signaturefd LLC now owns 45,311 shares of the company’s stock worth $644,000 after acquiring an additional 10,070 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in Takeda Pharmaceutical by 14.4% in the third quarter. Sequoia Financial Advisors LLC now owns 26,306 shares of the company’s stock worth $374,000 after purchasing an additional 3,318 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Takeda Pharmaceutical by 62.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 17,759 shares of the company’s stock valued at $253,000 after purchasing an additional 6,852 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $13.86 on Friday. The stock has a 50-day moving average of $14.42 and a 200-day moving average of $13.81. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. The company has a market cap of $44.10 billion, a PE ratio of 23.90, a P/E/G ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.